Zoledronic acid in genitourinary cancer
Clin. transl. oncol. (Print)
; 15(11): 871-878, nov. 2013.
Article
in English
| IBECS
| ID: ibc-127668
Responsible library:
ES1.1
Localization: BNCS
ABSTRACT
Bone metastases are a common complication of advanced prostate cancer and while they are less common in non-prostate genitourinary (GU) malignances, they have been reported in up to 35 % of patients with advanced renal cell carcinoma and bladder cancer. Furthermore, they may occur in more than two-thirds of those patients with bladder cancer who develop distant metastases. In the absence of bone-targeted therapies, approximately 50 % of all patients with metastatic bone disease from GU cancers experience at least one skeletal-related event within their lifetime. Zoledronic acid is a bisphosphonate that has been shown to delay or prevent the development of skeletal complications in patients with bone metastases and reduce bone pain in these patients. Furthermore, zoledronic acid has also demonstrated the ability to prevent osteopenia, which may occur with the prolonged use of some pharmacological interventions in patients with cancer (AU)
Search on Google
Collection:
National databases
/
Spain
Health context:
SDG3 - Target 3.4 Reduce premature mortality due to noncommunicable diseases
Health problem:
Bladder Cancer
/
Prostate Cancer
Database:
IBECS
Main subject:
Prostatic Neoplasms
Type of study:
Diagnostic study
Limits:
Humans
/
Male
Language:
English
Journal:
Clin. transl. oncol. (Print)
Year:
2013
Document type:
Article
Institution/Affiliation country:
Complejo Hospitalario Universitario Santiago de Compostela/Spain
/
Hospital Clínico Universitario San Carlos/Spain
/
Hospital Reina Sofía/Spain
/
Instituto Valenciano de Oncología (IVO)/Spain